Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pfizer Inc. stock logo
PFE
Pfizer
$27.29
+0.4%
$26.87
$25.20
$40.37
$154.53B0.6342.16 million shs7.85 million shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pfizer Inc. stock logo
PFE
Pfizer
+6.09%+3.47%-1.91%-0.40%-30.44%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Pfizer Inc. stock logo
PFE
Pfizer
4.9787 of 5 stars
3.23.04.24.83.11.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.3333.14% Upside

Current Analyst Ratings

Latest PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
3/22/2024
Pfizer Inc. stock logo
PFE
Pfizer
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
2/23/2024
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$36.00
(Data available from 5/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.64$3.17 per share8.61$15.81 per share1.73

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3675.819.961.153.62%10.88%4.91%8/6/2024 (Estimated)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.16%+2.57%466.67%15 Years

Latest PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

PFE Headlines

SourceHeadline
Victory Capital Management Inc. Grows Position in Pfizer Inc. (NYSE:PFE)Victory Capital Management Inc. Grows Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - May 2 at 8:59 AM
Pfizer Stock: Finally The Market Is Waking UpPfizer Stock: Finally The Market Is Waking Up
seekingalpha.com - May 2 at 8:29 AM
3 Contrarian Stocks That Could Make You a Fortune (If You Dare)3 Contrarian Stocks That Could Make You a Fortune (If You Dare)
investorplace.com - May 2 at 7:22 AM
My Top 5 Favorite High-Yield Dividend Stocks to Buy in MayMy Top 5 Favorite High-Yield Dividend Stocks to Buy in May
fool.com - May 2 at 5:50 AM
Pfizers Stock Is a Buy. Here Are Six Reasons Why.Pfizer's Stock Is a Buy. Here Are Six Reasons Why.
fool.com - May 2 at 5:15 AM
Q1 2024 Pfizer Inc Earnings Call TranscriptQ1 2024 Pfizer Inc Earnings Call Transcript
gurufocus.com - May 2 at 1:01 AM
Raymond James Financial Services Advisors Inc. Grows Stake in Pfizer Inc. (NYSE:PFE)Raymond James Financial Services Advisors Inc. Grows Stake in Pfizer Inc. (NYSE:PFE)
marketbeat.com - May 1 at 11:16 PM
Pfizer stock gains 7% after earnings beat, company calls dividend securePfizer stock gains 7% after earnings beat, company calls dividend 'secure'
msn.com - May 1 at 8:39 PM
Pfizer (PFE) Q1 2024 Earnings Call TranscriptPfizer (PFE) Q1 2024 Earnings Call Transcript
fool.com - May 1 at 8:39 PM
Why Pfizer Stock Blasted More Than 6% Higher TodayWhy Pfizer Stock Blasted More Than 6% Higher Today
fool.com - May 1 at 5:55 PM
PFE Earnings: Pfizer Rises After Smashing Q1 EstimatesPFE Earnings: Pfizer Rises After Smashing Q1 Estimates
msn.com - May 1 at 3:39 PM
Pfizer (NYSE:PFE) Stock Price Up 3.8%Pfizer (NYSE:PFE) Stock Price Up 3.8%
marketbeat.com - May 1 at 1:59 PM
Pfizer Stock Gets Boost From Better-Than-Expected EarningsPfizer Stock Gets Boost From Better-Than-Expected Earnings
investopedia.com - May 1 at 1:46 PM
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance RaisedPfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
zacks.com - May 1 at 12:46 PM
Pfizer raises guidance amid cost savingsPfizer raises guidance amid cost savings
msn.com - May 1 at 10:38 AM
Pfizer Stock Rises as Outlook Rises After Earnings BeatPfizer Stock Rises as Outlook Rises After Earnings Beat
finance.yahoo.com - May 1 at 10:38 AM
Pfizer Inc (PFE) Q1 2024 Earnings: Adjusted EPS Surpasses Expectations Amidst Revenue DeclinePfizer Inc (PFE) Q1 2024 Earnings: Adjusted EPS Surpasses Expectations Amidst Revenue Decline
finance.yahoo.com - May 1 at 10:38 AM
Stocks to Watch Wednesday: Starbucks, Pfizer, CVS, AmazonStocks to Watch Wednesday: Starbucks, Pfizer, CVS, Amazon
finance.yahoo.com - May 1 at 10:38 AM
Pfizer raises full-year outlook, stock rises on Q1 beatPfizer raises full-year outlook, stock rises on Q1 beat
finance.yahoo.com - May 1 at 10:38 AM
Pfizer (PFE) Reports Q1 Earnings: What Key Metrics Have to SayPfizer (PFE) Reports Q1 Earnings: What Key Metrics Have to Say
zacks.com - May 1 at 10:35 AM
Pfizer (NYSE:PFE) Releases FY24 Earnings GuidancePfizer (NYSE:PFE) Releases FY24 Earnings Guidance
marketbeat.com - May 1 at 9:35 AM
Pfizer (PFE) Q1 Earnings and Revenues Beat EstimatesPfizer (PFE) Q1 Earnings and Revenues Beat Estimates
zacks.com - May 1 at 8:55 AM
Pfizer revenues fall 19% due to lower COVID-related product demandPfizer revenues fall 19% due to lower COVID-related product demand
proactiveinvestors.com - May 1 at 8:14 AM
Pfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid salesPfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid sales
cnbc.com - May 1 at 7:13 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.